Semler Scientific — Needham Virtual Healthcare Conference April 2023
22 slides from Semler Scientific's conference presentation, Apr 17, 2023

Slide 1: Needham Virtual Healthcare Conference April 2023
NASDAQ:SMLR Needham Virtual Healthcare Conference April 2023

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believe,” “estimate,” “anticipate,” “expect,” “

Slide 3: Investment Highlights
Investment Highlights (in millions of U.S. Dollars) Solid track record of growth and profitability • Recurring SAAS revenue model • Strong cash position of $43.1 million as of 12/31/22 • Reinvest in business • Diversity products • Share buybacks 3 2018 2022 REVENUES INCOME FROM OPERATIONS $56.7m $21

Slide 4: Disruptive, Paradigm-shifting Business with Large Opportunity
Disruptive, Paradigm-shifting Business with Large Opportunity Technology to bring cardiac and vascular testing to the front lines of medicine High-leverage distribution model supporting value-based healthcare companies such as Health Insurance Plans and other emerging customers Software as a service

Slide 5: QuantaFlo Product Family Comparison
QuantaFlo Product Family Comparison QuantaFlo® QuantaFlo® HD Aids in the diagnosis: for Peripheral Artery Disease (PAD) for Heart dysfunction (HD) Market Introduction 2011 2022 Regulatory Status FDA cleared Point of Service Office, clinic, home Hardware PC, laptop or tablet + sensor Test administere

Slide 6: New Investments
New Investments Insulin Insights™ Entered into an exclusive distribution agreement with Mellitus Health in the U.S., including Puerto Rico, except selected accounts. Insulin Insights™ is an FDA-cleared software solution designed to provide healthcare providers optimal insulin dosing recommendations

Slide 7: Recurring Revenue SAAS Model
Recurring Revenue SAAS Model 7 • Two types of recurring revenue depending on customer type: • Monthly fixed-fees • Variable-fees or fee-per-test based on usage (plus cost of sensor) • Offering enterprise solutions, such as EMR integration; results in high customer retention • Opportunity to introduc

Slide 8: Bringing Cardiovascular Testing to the Front Lines of Medicine
Bringing Cardiovascular Testing to the Front Lines of Medicine 8 5 Minute Test • FDA marketing clearance and patent granted • Well-suited for use in primary care & specialty practices, health fairs and during in home evaluations • Delivers fast, clinically-proven, accurate results in ~5 minutes by a

Slide 9: Competition in the Peripheral Arterial Disease (PAD) Market
Competition in the Peripheral Arterial Disease (PAD) Market • Traditional Ankle-Brachial Index (ABI) testing for PAD has been the standard for decades, uses blood pressure cuffs and doppler ultrasound imaging • Requires a trained vascular technician, performed by referral in a specialized vascular l

Slide 10: Traditional Method to Identify Heart Dysfunction
Traditional Method to Identify Heart Dysfunction • Traditional transthoracic echocardiograph (Echo) testing for heart dysfunction • Requires a trained sonographer to perform the test, performed by referral in a specialized lab, takes about an hour, must be read by a primary care physician or cardiol

Slide 11: Business Opportunity
Business Opportunity 11 • More than 400K medical professionals practicing primary care medicine in the U.S. • We believe there are 80+ million people in U.S. who, based on AHA/ACC criteria could be tested: • 64 million age 65 or older, or • 10,000 people in the U.S. turn 65 every day • Age 50 to 64

Slide 12: Early Warning
Early Warning 12 Society benefits from “early warning” of patients’ health status: • Start preventive care to avoid acute care costs down the road • Improved economics to mitigate the financial costs of heart attacks, strokes and chronic disease • Opportunity to promote health equity and improve dis

Slide 13: Realities of PAD
Realities of PAD 13 • PAD is highly underdiagnosed • >30% of patients over age 65 screen positive for PAD3 • 75% of PAD patients are asymptomatic4 - primary MDs often miss the diagnosis • PAD sufferers have a 21% increased risk of a heart attack, stroke, hospitalization or death within one year5 • C

Slide 14: Delaying Testing for PAD Allows Progression
Delaying Testing for PAD Allows Progression 14 • PAD screening is a reasonable medical intervention with an acceptable cost in a CMS patient population.7 • There is enormous potential to realize cost-savings by reducing cardiovascular event rates and deploying population-based PAD risk management st

Slide 15: Recent Independent Clinical Studies Supports Use of QuantaFlo
Recent Independent Clinical Studies Supports Use of QuantaFlo® Two independently conducted; peer-reviewed studies published in 2022 analyzed screening tests using QuantaFlo® to aid in the diagnosis of PAD 15 1 - • The “HouseCalls Program” published in the AJPM Focus9 tested 192,500 patients in their

Slide 16: Realities of Heart Failure
Realities of Heart Failure 16 • Heart failure is highly underdiagnosed. Prevalence rate of identifying patients over age 65 of asymptomatic pre-heart failure with a structural or functional abnormality is 30-40%11 • The number of patients with asymptomatic heart failure exceeds the number of patient

Slide 17: Introducing Dr. Wayne Pan, CEO
Introducing 17 Dr. Wayne Pan, CEO

Slide 18: CMS 2024 Final Rate Announcement for Medicare Advantage Capitation Rates
CMS 2024 Final Rate Announcement for Medicare Advantage (MA) Capitation Rates

Slide 19: Future Focus
Future Focus 19 1. Clinical Messaging 2. Value Base Care and Potential to Reduce Healthcare Costs 3. Expanding our Target Patient Population 4. Health Equity 5. New Products including QuantaFlo HD and Insulin Insights

Slide 20: Maximize Stockholder Returns
Maximize Stockholder Returns 20 • Reinvest in core business – reinforce clinical message, add additional customers, invest in QuantaFlo® HD and new products • Diversify Product Range – through license deals, investments and acquisitions • Share Buybacks – $20m total share buyback authorization; $15m

Slide 21: Sources Appendix 2
Sources Appendix 2221 1. Howell SC, Master RC (2023) Clinical Evaluation of Volume Plethysmography as an Aid for Diagnosis of Heart Failure in the Primary Care Setting. J Prev Med Vol.8 No.1: 184 2. https://www.commonwealthfund.org/blog/2022/taking-stock-medicare-advantage-overview; https://arc.aarp

Slide 22: Contact: [email protected]
Contact: [email protected]
Source: SEC EDGAR · 8-K filed Apr 17, 2023




